Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552469 · ClinicalTrials.gov registry record · Phase 1
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
A Phase 1 study of Myeloid Diseases, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 20
- Study locations
NCT05552469 is a Phase 1 study of Myeloid Diseases that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 62 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT05552469, a Phase 1 study of Myeloid Diseases, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of three groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS), lower risk chronic myelomonocytic leukemia (LR CMML) and High-Risk Clonal Cytopenia of Undetermined Significance (HR CCUS).
Conditions Studied
Interventions
- DRUG DFV890
Study Locations (20)
Other
- Novartis Investigative Site - Grenoble
- Novartis Investigative Site - Nantes
- Novartis Investigative Site - Paris
- Novartis Investigative Site - Lübeck
- Novartis Investigative Site - Hong Kong
New York
- Weill Cornell Medicine NY-Presb - New York
- Memorial Sloan Kettering Cancer Ctr - New York
Saxony
- Novartis Investigative Site - Dresden
- Novartis Investigative Site - Leipzig
California
- Stanford Cancer Center - Stanford
Florida
- H Lee Moffitt Cancer Center and Research Institute - Tampa
Illinois
- Northwestern University - Chicago
Maryland
- Sidney Kimmel CCC At JH - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2023-05-08 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05552469
The ClinicalTrials.gov registry entry for NCT05552469 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myeloid Diseases appearing as the primary indexed condition, and to 1 intervention - of which DFV890 is the first listed.
NCT05552469 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, New York, Saxony.
Frequently Asked Questions
What is clinical trial NCT05552469 about?
NCT05552469 is a clinical study titled "Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases". Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of three groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics,...
What is the current status of trial NCT05552469?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2023-05-08. Estimated completion is 2027-02-01.
What conditions does trial NCT05552469 study?
This clinical trial studies the following conditions: Myeloid Diseases.
What interventions are being tested in trial NCT05552469?
The interventions under investigation include: DFV890 (DRUG).
Who is sponsoring clinical trial NCT05552469?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05552469 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloid Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.